ARTICLE | Company News

AstraZeneca, University of Texas MD Anderson Cancer Center deal

February 9, 2015 8:00 AM UTC

AstraZeneca partnered with MD Anderson to evaluate undisclosed compounds from AZ’s pipeline in clinical and clinically related studies in ovarian and gynecologic cancers. Under the three-year deal, AZ is providing undisclosed funding, with at least 25% of the funding designated for non-clinical, clinically related research studies, such as non-interventional cost-effectiveness and epidemiological studies. A joint steering committee will be comprised of senior AZ executives and clinicians/scientists at MD Anderson. AZ retains commercial rights, and MD Anderson will have the right to use the data for internal, non-commercial research and academic purposes and to publish data in accordance with the deal. ...